- Trials with a EudraCT protocol (345)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
345 result(s) found for: Symptoms of COVID-19.
Displaying page 1 of 18.
EudraCT Number: 2020-001783-28 | Sponsor Protocol Number: BCG-COVID_HU_001 | Start Date*: 2020-05-06 |
Sponsor Name:National Korányi Institute of Pulmonology | ||
Full Title: REDUCING ABSENCE FROM WORK OF HEALTHCARE WORKERS DUE TO COVID-19 INFECTION BY BCG (BACILLUS CALMETTE-GUÉRIN) VACCINATION | ||
Medical condition: healthy volunteers working in the healthcare treating patients with new type of coronavirus (SARS-CoV-2) infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005759-18 | Sponsor Protocol Number: CV43043 | Start Date*: 2021-05-10 | |||||||||||
Sponsor Name:F. Hoffmann La Roche Ltd. | |||||||||||||
Full Title: A MULTICENTER, PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OUTPATIENT STUDY TO EVALUATE THE EFFICACY, SAFETY, AND ANTIVIRAL ACTIVITY OF RO7496998 AT-527 IN PATIENTS WITH MILD OR MODERAT... | |||||||||||||
Medical condition: Mild to Moderate coronavirus disease 2019 (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) DK (Prematurely Ended) FR (Prematurely Ended) PT (Prematurely Ended) IT (Prematurely Ended) RO (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000627-12 | Sponsor Protocol Number: CV43140 | Start Date*: 2021-06-01 | |||||||||||
Sponsor Name:F. Hoffmann La Roche Ltd. | |||||||||||||
Full Title: A MULTICENTER, OBSERVATIONAL, 6 MONTH FOLLOW-UP STUDY OF PATIENTS WITH COVID 19 PREVIOUSLY ENROLLED IN A RO7496998 (AT-527) STUDY | |||||||||||||
Medical condition: Coronavirus disease 2019 (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) PT (Prematurely Ended) DK (Completed) DE (Completed) IT (Prematurely Ended) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-004016-26 | Sponsor Protocol Number: Clin_COVID-19_Corok | Start Date*: 2021-10-18 |
Sponsor Name:Meilahti Vaccine Research Center - Helsinki University Hospital | ||
Full Title: Substudy "Responses to Covid-19 vaccines" in research "Clinical picture, immunology, genetics and pathogenesis of COVID-19 infection" | ||
Medical condition: None | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000781-15 | Sponsor Protocol Number: COVFATI | Start Date*: 2021-12-14 |
Sponsor Name:Amsterdam UMC VUmc | ||
Full Title: Neuroinflammation and post-infectious fatigue in individuals with and without Covid-19 | ||
Medical condition: Chronic fatigue after COVID-19 infection | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001610-38 | Sponsor Protocol Number: JAGG2020-1 | Start Date*: 2020-09-16 | |||||||||||
Sponsor Name:Slagelse Sygehus | |||||||||||||
Full Title: Irbesartan and Oseltamivir treatment of COVID-19 infection. | |||||||||||||
Medical condition: The combined treatment in this trial will be used to treat patients with Covid-19 infection in order to prevent the patients need for further treatment in a hospital. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-004166-37 | Sponsor Protocol Number: 100424 | Start Date*: 2023-05-02 |
Sponsor Name:Division of Thoracic and Hyperbaric Surgery, Medical University Graz | ||
Full Title: Hyperbaric oxygenation for patients with orthostatic dysregulation (postural orthostatic tachycardia) in Long- COVID. Prospectively randomized cross- over study. | ||
Medical condition: Multiorgan symptoms after COVID-19 infection (Long COVID) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-005366-34 | Sponsor Protocol Number: WV43042 | Start Date*: 2021-02-12 | |||||||||||
Sponsor Name:F. Hoffmann La Roche Ltd. | |||||||||||||
Full Title: A PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE ANTIVIRAL ACTIVITY, SAFETY, PHARMACOKINETICS, AND EFFICACY OF RO7496998 (AT-527) IN NON-HOSPITALIZED ADULT PATIENTS WI... | |||||||||||||
Medical condition: Coronavirus disease 2019 (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) BG (Completed) ES (Completed) LV (Completed) GR (Completed) LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006485-20 | Sponsor Protocol Number: CHANCE | Start Date*: 2023-02-22 | |||||||||||
Sponsor Name:URSAPHARM Arzneimittel GmbH | |||||||||||||
Full Title: COVID-19: Reducing Symptoms and Hospitalization rates by use of Azelastine Nasal spray in patients suffering from COVID-19 in Early stages | |||||||||||||
Medical condition: Diagnosis of SARS-CoV-2 infection documented by a positive PCR test (patients do not need to suffer from COVID-19 symptoms) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002827-36 | Sponsor Protocol Number: C4671042 | Start Date*: 2023-02-10 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: AN INTERVENTIONAL, EFFICACY AND SAFETY, PHASE 2, RANDOMIZED, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE A REPEAT 5-DAY COURSE OF NIRMATRELVIR/RITONAVIR COMPARED TO PLACEBO/RITONAVIR IN PARTICIPANTS A... | |||||||||||||
Medical condition: SARS-CoV-2 Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006005-30 | Sponsor Protocol Number: APG101_CD_018 | Start Date*: 2022-09-22 | |||||||||||
Sponsor Name:Apogenix AG | |||||||||||||
Full Title: A Multicenter, Randomized, Placebo-controlled, Double-blind, Phase III Trial to Evaluate the Efficacy of Asunercept for the Treatment of Hospitalized Patients with Moderate to Severe COVID-19 Disease | |||||||||||||
Medical condition: Moderate to Severe COVID-19 Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) DE (Completed) AT (Prematurely Ended) FR (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002857-28 | Sponsor Protocol Number: C4671002 | Start Date*: 2021-08-23 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTI... | |||||||||||||
Medical condition: Coronavirus Disease 2019 (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) HU (Completed) BG (Completed) CZ (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002208-37 | Sponsor Protocol Number: HVH237CIMM-COVID19 | Start Date*: 2021-04-29 | |||||||||||
Sponsor Name:Respiratory Research Unit 237, Hvidovre Hospital | |||||||||||||
Full Title: The CIMMCov-study: A Single-center, Double-blinded, Randomized, 28-days, Parallel-group, study to evaluate the effect of Ciclesonide 320 mcg inhalation twice daily versus placebo on healthcare util... | |||||||||||||
Medical condition: COVID-19 pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000890-10 | Sponsor Protocol Number: MP0420-CP302 | Start Date*: 2021-05-03 | |||||||||||
Sponsor Name:Molecular Partners AG | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, multicenter study of ensovibep (MP0420) in ambulatory adult patients with symptomatic COVID-19 | |||||||||||||
Medical condition: Symptomatic COVID-19 in ambulatory patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006621-22 | Sponsor Protocol Number: COVIC-19-G | Start Date*: 2022-02-14 | |||||||||||
Sponsor Name:DRK-Blutspendedienst Baden-Württemberg - Hessen gGmbH | |||||||||||||
Full Title: A Randomised Open-Label Trial of Early, Very High-Titre Convalescent Plasma Therapy in Clinically Vulnerable Individuals with Mild COVID-19 as model of early treatment in a pandemia with a new path... | |||||||||||||
Medical condition: Clinically Vulnerable Individuals with Mild COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000904-39 | Sponsor Protocol Number: MK-4482-013 | Start Date*: 2021-08-11 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 (Laboratory-confirmed SARS-CoV-2 Infection W... | |||||||||||||
Medical condition: Prophylaxis of COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) FR (Completed) HU (Completed) BG (Completed) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001678-31 | Sponsor Protocol Number: APHP200462 | Start Date*: 2020-04-28 |
Sponsor Name:Assistance Publique Hopitaux de Paris | ||
Full Title: Randomized controlled trial evaluating the efficacy of vaccination with Bacillus Calmette and Guérin (BCG) in the Prevention of COVID-19 via the strengthening of innate immunity in Health Care Work... | ||
Medical condition: COVID 19 Health care workers (medical or non-medical) in French hospitals in direct contact with COVID-19 patients, including nurses, medical doctors and other personnel working in wards in charge... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001697-30 | Sponsor Protocol Number: COVIDNA | Start Date*: 2020-04-23 |
Sponsor Name:NAVARRABIOMED - FUNDACIÓN MIGUEL SERVET | ||
Full Title: PRE-EXPOSURE PROPHYLAXIS WITH HYDROXYCHLOROQUINE IN SANITARIES HIGHLY EXPOSED TO COVID-19. (COVIDNA) | ||
Medical condition: PRE-EXPOSURE PROPHYLAXIS WITH HYDROXYCHLOROQUINE IN SANITARIES HIGHLY EXPOSED TO COVID-19 | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002123-11 | Sponsor Protocol Number: HUIS-04-2020 | Start Date*: 2020-05-07 | |||||||||||
Sponsor Name:Tatiana Cobo Ibáñez [...] | |||||||||||||
Full Title: EFFICACY OF CYCLOSPORINE IN THE TREATMENT OF COVID-19 PNEUMONIA: A RANDOMIZED CONTROLLED TRIAL. | |||||||||||||
Medical condition: COVID-19 PNEUMONIA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001938-19 | Sponsor Protocol Number: mdc-TTG-CT-002 | Start Date*: 2022-03-10 | |||||||||||
Sponsor Name:MedinCell S.A. | |||||||||||||
Full Title: A multicentre randomised, Double-Blind, Placebo-controlled, Study to evaluate the efficAcy and safety of oral IVErmectin tablets in the prevention of COVID-19 (the SAIVE Trial) | |||||||||||||
Medical condition: Prophylaxis of COVID-19 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
